Quote:

---

" Research reveals that persistent low-level inflammation, which is twice as common as elevated blood cholesterol levels, plays a part in every stage of heart disease including increasing the risk of plaque rupture which leads to heart attacks. In fact, half of all heart attacks occur in people with normal cholesterol levels."

---

Not only does leronlimab control inflammation but increases HDL (good) cholesterol and lowers LDL (bad) cholesterol. When it comes to the plaques of atherosclerosis leronlimab downregulates a lot of the associated chemokines responsible - VCAM-1, ICAM-1, IFN-y, TNF-a, LFA-1, TGF-b, IFN-a, GM-CSF etc.